Danish Society for Biopharmaceutical Statistics

The Danish Society for Biopharmaceutical Statistics (DSBS) was formed in March 1992 as an independent non-profit association. The aims of DSBS are to further the exchange of information between professional statisticians working for the pharmaceutical industry in Denmark and abroad, to promote professional standards, and to constitute an expert body in biopharmaceutical statistical matters. About 150 statisticians, representing 13 companies, are members of the society


Coming events


DSBS Course in Estimating Sample Sizes in Clinical Trials

12-13 April 2018

Deadline 1 April 2018

Read more in the flyer: Sample Size Course Flyer 2018

DSBS Annual Meeting 2018

on 19 April 2018 at 16:00 - 19:00

After the meeting, we would like you to join us for dinner at the same venue.

Venue: Cosmopol, Fiolstræde 44 (at Nørreport)

Read more in the flyer: Annual Meeting 2018 Flyer

Recent events

Two-part DSBS Course: Survival Analysis in Clinical Trials

Part Downloads
Part 1: 17-18 January 2018 Link to downloads for Part 1
Part 2: 31 January - 1 February 2018 Link to downloads for Part 2


Draft ICH E9 addendum on
Estimands and Sensitivity Analysis

Monday, 20 November 2017, 15:00 at Lundbeck A/S

DSBS plans to comment on the draft addendum to ICH E9 via EFSPI

Link to guideline: ICH E9 (R1) addendum on estimands and sensitivity analysis


Presentations from half-day meeting on Estimands
26 Oct 2017

Speaker Presentation as pdf
Agenda Detailed program
Frank Bretz How the ICH E9 addendum around estimands may impact our clinical trials
Søren Andersen & Helle Lynggaard Implementation of estimands in Novo Nordisk
Mette Krog Josiassen Applying estimand strategies in schizophrenia


Presentations from DSBS 25th Anniversary
31 March 2017

Speaker Presentation as pdf
Agenda Detailed program
Karsten Schmidt, Claus Bay & Merete Jørgensen Biostatistics in the regulatory environment and the formation of DSBS in the 1990’s
Ralf Bender, Institute for Quality and Efficiency in Health Care (IQWiG) Evaluation of subgroup analyses in the framework of benefit assessment
Erik Doffagne, CluePoints Using central statistical monitoring to drive quality into clinical trials
Nedjad Losic, Genmab Two Bayesian designs for first-in-human trials in cancer
Anders Malmberg, Ferring A phase II trial with response-adaptive allocation
Lasse Sluth, Lundbeck and Lars Endahl, Novo Nordisk Regulatory interaction with Asia